AbbVie halts late-stage trial for lung cancer drug Rova-T

AbbVie said on Wednesday it had halted enrollment for a late stage trial of Rova-T as a second-line therapy for advanced small-cell lung cancer, following recommendations made by an independent data monitoring committee.